Angiotensin IIaldosterone interaction in human coronary microarteries involves GPR30, EGFR, and endothelial NO synthase

Cardiovascular Research

Volumn 94, Issue 1, 2012, Pages 136-143

  Batenburg, Wendy W ^a   Jansen, Pieter M ^a   Van Den Bogaerdt, Antoon J ^a   Danser, Alexander H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

17 oestradiol; Aldosterone; EGF receptor; GPR30; Human coronary arteries; NO

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALDOSTERONE; ANGIOTENSIN II; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; G 15; G PROTEIN COUPLED RECEPTOR 30; HYDROCORTISONE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GPER PROTEIN, HUMAN; HORMONE ANTAGONIST; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NOS3 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONCENTRATION (PARAMETERS); CORONARY ARTERY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MYOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SCHOOL CHILD; SMOOTH MUSCLE CONTRACTION; ARTERIOLE; CELL CULTURE; CORONARY BLOOD VESSEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYMOLOGY; HEART MUSCLE; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; SIGNAL TRANSDUCTION; VASOCONSTRICTION;

ADOLESCENT; ADULT; AGED; ALDOSTERONE; ANGIOTENSIN II; ARTERIOLES; CELLS, CULTURED; CHILD; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENDOTHELIAL CELLS; ENZYME ACTIVATION; ESTRADIOL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HORMONE ANTAGONISTS; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; MYOCARDIUM; MYOGRAPHY; NITRIC OXIDE SYNTHASE TYPE III; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; VASOCONSTRICTION; YOUNG ADULT;

EID: 84859050870     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs016     Document Type: Article

References (55)

1. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
2. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
3. Chai W, Danser AHJ. Why are mineralocorticoid receptor antagonists cardioprotective? Naunyn Schmiedebergs Arch Pharmacol 2006;374:153-162
4. Favre J, Gao J, Zhang AD, Remy-Jouet I, Ouvrard-Pascaud A, Dautreaux B et al. Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. Am J Physiol Heart Circ Physiol 2011;300:H2035-H2043.
5. Chai W, Hofland J, Jansen PM, Garrelds IM, de Vries R, van den Bogaerdt AJ et al. Steroidogenesis vs. steroid uptake in the heart: do corticosteroids mediate effects via cardiac mineralocorticoid receptors? J Hypertens 2010;28:1044-1053.
6. Chai W, Garrelds IM, de Vries R, Batenburg WW, van Kats JP, Danser AHJ. Nongenomic effects of aldosterone in the human heart. Interaction with angiotensin II. Hypertension 2005;46:701-706.
7. Schmidt BMW, Sammer U, Fleischmann I, Schlaich M, Delles C, Schmieder RE. Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension 2006;47:650-655.
8. Schmidt BMW, Oehmer S, Delles C, Bratke R, Schneider MP, Klingbeil A et al. Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 2003; 42:156-160.
9. Sawathiparnich P, Murphey LJ, Kumar S, Vaughan DE, Brown NJ. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. J Clin Endocrinol Metab 2003;88:3867-3873.
10. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 2003;108:2400-2406.
11. Xiao F, Puddefoot JR, Barker S, Vinson GP. Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation. Hypertension 2004;44:340-345.
12. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 2005;97:434-442.
13. Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G et al. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 2008;28:1511-1518.
14. Min LJ, Mogi M, Iwanami J, Li JM, Sakata A, Fujita T et al. Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence. Cardiovasc Res 2007; 76:506-516.
15. Yamada M, Kushibiki M, Osanai T, Tomita H, Okumura K. Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization. Cardiovasc Res 2008;79:169-178.
16. Mazak I, Fiebeler A, Müller DN, Park JK, Shagdarsuren E, Lindschau C et al. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 2004;109:2792-2800.
17. Griol-Charhbili V, Fassot C, Messaoudi S, Perret C, Agrapart V, Jaisser F. Epidermal growth factor receptor mediates the vascular dysfunction but not the remodeling induced by aldosterone/salt. Hypertension 2011;57:238-244.
18. Kusche-Vihrog K, Callies C, Fels J, Oberleithner H. The epithelial sodium channel (ENaC): Mediator of the aldosterone response in the vascular endothelium? Steroids 2010;75:544-549.
19. Lemarie CA, Simeone SM, Nikonova A, Ebrahimian T, Deschenes ME, Coffman TM et al. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res 2009;105:852-859.
20. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005;45: 773-779.
21. Lopez-Andres N, Inigo C, Gallego I, Diez J, Fortuno MA. Aldosterone induces cardiotrophin-1 expression in HL-1 adult cardiomyocytes. Endocrinology 2008;149: 4970-4978.
22. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N et al. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J 2010;24:2454-2463.
23. Gros R, Ding Q, Sklar LA, Prossnitz EE, Arterburn JB, Chorazyczewski J et al. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension 2011;57:442-451.
24. Ullian ME, Walsh LG, Morinelli TA. Potentiation of angiotensin II action by corticosteroids in vascular tissue. Cardiovasc Res 1996;32:266-273.
25. Leclerc PC, Lanctot PM, Auger-Messier M, Escher E, Leduc R, Guillemette G. S-nitrosylation of cysteine 289 of the AT1 receptor decreases its binding affinity for angiotensin II. Br J Pharmacol 2006;148:306-313.
26. Chakrabarti S, Lekontseva O, Peters A, Davidge ST. 17-{beta}-Estradiol induces protein S-nitrosylation in the endothelium. Cardiovasc Res 2010;85:796-805.
27. Xiao D, Huang X, Yang S, Zhang L. Direct chronic effect of steroid hormones in attenuating uterine arterial myogenic tone: role of protein kinase c/extracellular signalregulated kinase 1/2. Hypertension 2009;54:352-358.
28. Stewart JA Jr, Cashatt DO, Borck AC, Brown JE, Carver WE. 17beta-estradiol modulation of angiotensin II-stimulated response in cardiac fibroblasts. J Mol Cell Cardiol 2006;41:97-107.
29. Batenburg WW, de Vries R, Saxena PR, Danser AHJ. L-S-nitrosothiols: endotheliumderived hyperpolarizing factors in porcine coronary arteries? J Hypertens 2004;22: 1927-1936.
30. Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L, van Kats JP, Saxena PR et al. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 2004;109:2296-2301.
31. Batenburg WW, Garrelds IM, van Kats JP, Saxena PR, Danser AHJ. Mediators of bradykinin-induced vasorelaxation in human coronary microarteries. Hypertension 2004;43:488-492.
32. Batenburg WW, Kappers MHW, Eikmann MJ, Ramzan SN, de Vries R, Danser AHJ. Light-induced vs. bradykinin-induced relaxation of coronary arteries: do Snitrosothiols act as endothelium-derived hyperpolarizing factors? J Hypertens 2009; 27:1631-1640.
33. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977;41:19-26.
34. Touyz RM, He G, Deng LY, Schiffrin EL. Role of extracellular signal-regulated kinases in angiotensin II-stimulated contraction of smooth muscle cells from human resistance arteries. Circulation 1999;99:392-399.
35. Saris JJ, Hoen PA, Garrelds IM, Dekkers DH, den Dunnen JT, Lamers JMJ et al. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 2006;48:564-571.
36. van den Eijnden MMED, Saris JJ, de Bruin RJA, de Wit E, Sluiter W, Reudelhuber TL et al. Prorenin accumulation and activation in human endothelial cells. Importance of mannose 6-phosphate receptors. Arterioscler Thromb Vasc Biol 2001;21:911-916.
37. Tom B, Garrelds IM, Scalbert E, Stegmann APA, Boomsma F, Saxena PR et al. ACEversus chymase-dependent angiotensin II generation in human coronary arteries: a matter of efficiency? Arterioscler Thromb Vasc Biol 2003;23:251-256.
38. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 2000;87:677-682.
39. Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, Chappell MC. Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology 2009;150:3753-3758.
40. Filardo EJ, Thomas P. GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab 2005;16:362-367.
41. Molnar GA, Lindschau C, Dubrovska G, Mertens PR, Kirsch T, Quinkler M et al. Glucocorticoid-related signaling effects in vascular smooth muscle cells. Hypertension 2008;51:1372-1378.
42. Heylen E, Huang A, Sun D, Kaley G. Nitric oxide-mediated dilation of arterioles to intraluminal administration of aldosterone. J Cardiovasc Pharmacol 2009;54:535-542.
43. Grossmann C, Freudinger R, Mildenberger S, Husse B, Gekle M. EF domains are sufficient for nongenomic mineralocorticoid receptor actions. J Biol Chem 2008;283: 7109-7116.
44. Huyet J, Pinon GM, Fay MR, Fagart J, Rafestin-Oblin ME. Structural basis of spirolactone recognition by the mineralocorticoid receptor. Mol Pharmacol 2007;72: 563-571.
45. Madeo A, Maggiolini M. Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res 2010;70:6036-6046.
46. Sirianni R, Chimento A, Ruggiero C, De Luca A, Lappano R, Ando S et al. The novel estrogen receptor, G protein-coupled receptor 30, mediates the proliferative effects induced by 17beta-estradiol on mouse spermatogonial GC-1 cell line. Endocrinology 2008;149:5043-5051.
47. Krug AW, Allenhofer L, Monticone R, Spinetti G, Gekle M, Wang M et al. Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways. Hypertension 2010;55:1476-1483.
48. Rowlands DJ, Chapple S, Siow RC, Mann GE. Equol-stimulated mitochondrial reactive oxygen species activate endothelial nitric oxide synthase and redox signaling in endothelial cells: roles for F-actin and GPR30. Hypertension 2011;57:833-840.
49. Lin AH, Leung GP, Leung SW, Vanhoutte PM, Man RY. Genistein enhances relaxation of the spontaneously hypertensive rat aorta by transactivation of epidermal growth factor receptor following binding to membrane estrogen receptors-alpha and activation of a G protein-coupled, endothelial nitric oxide synthase-dependent pathway. Pharmacol Res 2011;63:181-189.
50. Smith NJ, Chan HW, Qian H, Bourne AM, Hannan KM, Warner FJ et al. Determination of the exact molecular requirements for type 1 angiotensin receptor epidermal growth factor receptor transactivation and cardiomyocyte hypertrophy. Hypertension 2011;57:973-980.
51. Schuijt MP, de Vries R, Saxena PR, Danser AHJ. Prostanoids, but not nitric oxide, counterregulate angiotensin II mediated vasoconstriction in vivo. Eur J Pharmacol 2001;428:331-336.
52. Szekeres M, Nadasy GL, Kaley G, Koller A. Nitric oxide and prostaglandins modulate pressure-induced myogenic responses of intramural coronary arterioles. J Cardiovasc Pharmacol 2004;43:242-249.
53. Itskovitz J, Rubattu S, Rosenwaks Z, Liu HC, Sealey JE. Relationship of follicular fluid prorenin to oocyte maturation, steroid levels, and outcome of in vitro fertilization. J Clin Endocrinol Metab 1991;72:165-171.
54. Klotz S, Burkhoff D, Garrelds IM, Boomsma F, Danser AHJ. The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences? Eur Heart J 2009; 30:805-812.
55. ChaiW, Garrelds IM, de Vries R, Danser AHJ. Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone? Hypertension 2006;47:665-670.